secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vanda Pharmaceuticals Inc. (VNDA)
CIK:        0001347178
Form:       8-K
Filed at:   2025-10-29T23:59:59+00:00
Accession:  0001628280-25-047112
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vanda Q3 revenue up 18% to $56.3M but net loss widens to $22.6M; guidance lowered
--------------------------------------------------------------------------------

- Total net product sales $56.3M (+18% YoY): Fanapt $31.2M (+31%), HETLIOZ $18.0M (+1%), PONVORY $7.0M (+20%).
- Net loss $22.6M (diluted EPS -$0.38) vs loss $5.3M (-$0.09) in Q3 2024.
- FY2025 guidance: revenue $210-$230M (prev. $210-$250M); year-end cash $260-$290M (prev. $280-$320M).
- Pipeline: Tradipitant NDA PDUFA Dec 30, 2025; Bysanti NDA Feb 21, 2026; Imsidolimab BLA filing expected Q4 2025.
- Cash $293.8M at Sep 30, 2025, down $80.9M from Dec 31, 2024 and $31.8M from Jun 30, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347178/000162828025047112/0001628280-25-047112-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347178/000162828025047112/vnda-20251029.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-047112

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer